natgillin/translations-raw huggingface dataset:
In alignment with the effect on relapse rate, supportive analyses from Study 1 (CAMMS323) showed that LEMTRADA 12 mg/day led to significantly fewer LEMTRADA -treated patients experiencing severe relapses (61% reduction, p=0.0056) and signficantly fewer relapses that led to steroid treatment (58% reduction, p<0.0001) compared to IFNB-1a.
Podporne analize 1. študije (CAMMS323) so vzporedno z učinkom na stopnjo recidivov pokazale, da je odmerek zdravila LEMTRADA 12 mg/dan pomembno zmanjšal število bolnikov s hudimi recidivi (61- odstotno zmanjšanje, p=0,0056) in pomembno zmanjšal število recidivov, ki so privedli do zdravljenja s steroidi (58-odstotno zmanjšanje, p<0,0001) v primerjavi z IFNB-1a.
In all age groups the most frequently reported local adverse reactions after vaccination were pain (24.1% to 41.3%), redness (15.5% to 35.6%), and swelling (11.3% to 19.9%).
V vseh starostnih skupinah so bili najpogosteje opisani neželeni učinki po cepljenju bolečina (od 24,1 % do 41,3%), pordelost (od 15,5 % do 35,6 %) in oteklost (od 11,3 % do 19,9 %).
In all aHUS patients, eculizumab serum concentrations of approximately 50 - 100 microgram/ml are sufficient for essentially complete inhibition of terminal complement activity.
Pri vseh bolnikih z aHUS serumske koncentracije ekulizumaba približno 50–100 mikrogramov/ml zadoščajo za praktično popolno zavrtje aktivnosti terminalnega komplementa.
In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions.
Pomembno je, da zdravljenja ne zaključimo, dokler ni pregled kožnega ostružka, odvzet mesečno negativen 2 zaporedna meseca..
In all cases of splenic enlargement in HIV patients, this was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hypersplenism and no patients underwent splenectomy.
V vseh primerih je bilo povečanja vranice pri bolnikih z HIV blago do zmerno pri fizičnem pregledu, klinični potek pa je bil benigen; noben bolnik ni bil diagnosticiran s hipersplenizmom in nobenemu bolniku ni bila odstranjena vranica.
In all cases of splenic enlargement in HIV patients, this was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hypersplenism and no patients underwent splenectomy.
V vseh primerih je bilo povečanje vranice pri bolnikih s HIV blago do zmerno pri fizičnem pregledu, klinični potek pa je bil benigen; noben bolnik ni bil diagnosticiran s hipersplenizmom in nobenemu bolniku ni bila odstranjena vranica.
In all cases the last dose is given at least two weeks before the expected date of farrowing.
V vseh primerih pa se zadnji odmerek injicira vsaj dva tedna pred pričakovanim datumom prasitve.
In all cases this was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hyperplenism and no patients underwent splenectomy.
V vseh primerih je bilo povečanje pri fizičnem pregledu blago do zmerno, klinični potek pa je bil benigen; pri nobenemu bolniku niso diagnosticirali hipersplenizma in nobenemu bolniku niso odstranili vranice.
In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually taking into consideration other menopausal symptoms, effects on uterine and breast tissues, thromboembolic and cerebrovascular risks.
V vseh primerih je treba vsaj enkrat na leto opraviti skrbno presojo tveganj in koristi ob upoštevanju drugih simptomov menopavze, učinkov na tkivo maternice in dojk ter trombemboličnih in cerebrovaskularnih tveganj.
In all cases, dose should be adjusted according to therapeutic monitoring (see section 4.4.).
V vseh primerih je treba odmerek prilagoditi glede na terapevtsko spremljanje (glejte poglavje 4.4).
In all cases, dose should be adjusted according to therapeutic monitoring (see section 4.4.).
V vseh primerih je treba odmerjanje prilagoditi glede na terapevtsko spremljanje (glejte poglavje 4.4).
In all cases, the main measure of effectiveness was the disappearance of the markers of hepatitis virus infection from the blood after treatment and/or at ‘follow-up’ six months later.
V vseh primerih je bilo glavno merilo učinkovitosti izginotje označevalcev okužbe z virusom hepatitisa iz krvi po zdravljenju in/ali ob kontrolnem pregledu šest mesecev kasneje.
In all cases, the risks of the radiation should be less than from the disease itself.
V vsakem primeru je treba zagotoviti, da so tveganja zaradi sevanja manjša od same bolezni.
In all clinical assessments parecoxib was administered at a fixed time interval whereas the opioids were administered on as needs basis.
V vseh kliničnih ocenjevanjih so parekoksib uporabljali v določenih časovnih presledkih, opioide pa po potrebi.
In all clinical studies 38–40% of patients were  60 years of age and 10–12% of patients were
V vseh kliničnih študijah je bilo 38–40 % bolnikov starih  60 let, 10–12 % bolnikov pa je bilo starih
In all clinical studies, there was a significant increase in HbF from baseline after hydroxycarbamide use.
Pri vseh kliničnih študijah so opazili znaten porast HbF v primerjavi z izhodiščno točko po uporabi hidroksikarbamida,
In all clinical trials individuals who had received immunoglobulin or blood products within 3 months prior to the first vaccine dose were excluded.
Osebe, ki so v zadnjih 3 mesecih pred cepljenjem s prvim odmerkom cepiva prejele imunoglobuline ali izdelke iz krvi, so bile izključene iz vseh kliničnih preskušanj.
In all clinical trials individuals who had received immunoglobulin or blood-derived products within 3 months prior to the first vaccine dose were excluded.
Osebe, ki so v zadnjih 3 mesecih pred cepljenjem s prvim odmerkom cepiva prejele imunoglobuline ali izdelke iz krvi, so bile izključene iz vseh kliničnih preskušanj.
In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo.
Delež prekinitev zdravljenja zaradi neželenih učinkov je bil v vseh nadzorovanih študijah 12% med bolniki, ki so dobivali pregabalin, in 5% med bolniki, ki so dobivali placebo.
In all controlled trials, the discontinuation rate due to adverse reactions was 2.0% for patients receiving Qutenza and 0.9% for patients receiving control.
V vseh kontroliranih preskušanjih je bil delež bolnikov, ki so zaradi neželenih učnikov prekinili zdravljenje, 2,0 % pri bolnikih, ki so prejemali zdravilo Qutenza, in 0,9 % pri bolnikih, ki so prejemali kontrolno zdravilo.
In all five studies, patients randomized to the Raptiva dose group achieved statistically significantly better responses than placebo on the primary endpoint (PASI 75 response) (see Table 2 below) and on all the secondary efficacy endpoints.
V vseh petih študijah so bolniki naključno zbrani v skupine, ki so prejemale Raptivo dosegli statistično pomembno boljše rezultate za primarni cilj študij (PASI 75 odziv) (glejte spodaj tabelo 2 ) in sekundarne cilje učinkovitosti, kot bolniki, ki so prejemali placebo.
In all five studies, the main measure of effectiveness was based on changes in the patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).
V vseh petih študijah je glavno merilo učinkovitosti temeljilo na spremembah forsiranega ekspiracijskega volumna pri bolnikih (FEV1, največji volumen zraka, ki ga oseba lahko izdihne v eni sekundi).
In all four studies, Bydureon was more effective than the comparator treatments at reducing the levels of HbA1c in the blood.
V vseh štirih študijah je bilo zdravilo Bydureon pri zniževanju ravni HbA1c v krvi učinkovitejše kot primerjalna zdravila.
In all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).
Pri vseh primerih, kjer so prekinili odmerjanje zaradi zvišanih transaminaz in ga pozneje nadaljevali, se je lahko pozneje odmerjanje ivakaftorja uspešno nadaljevalo (glejte poglavje 4.4).
In all multiple sclerosis studies Extavia was effective in reducing disease activity (acute inflammation in the central nervous system and permanent tissue alterations) as measured by magnetic resonance imaging (MRI).
V vseh študijah multiple skleroze je zdravilo Extavia učinkovito zmanjšalo aktivnost bolezni (akutno vnetje v osrednjem živčevju in trajne spremembe tkiva), merjeno z magnetnoresonančnim slikanjem (MRS).
In all of the above cases Levetiracetam ratiopharm 100 mg/ml oral solution should be used.
V vseh zgoraj naštetih primerih se priporoča uporaba peroralne raztopine Levetiracetam ratopharm 100 mg/ml.
In all of the studies, the effectiveness was measured by looking at the number of patients who either had blood clots in the veins or in the lungs, or who died of any cause during the treatment period.
V vseh študijah so učinkovitost zdravila merili na podlagi števila bolnikov, ki so imeli krvne strdke v venah ali pljučih oziroma ki so med zdravljenjem zaradi katerega koli razloga umrli.
In all of the studies, the immunised pigs were compared with pigs that were castrated.
Cepljene prašiče so v vseh študijah primerjali s prašiči, ki so bili kastrirani.
In all of the studies, the main measure of effectiveness was based on the degree of itching and redness in the eye.
V vseh študijah je glavno merilo učinkovitosti temeljilo na intenzivnosti srbenja in pordelosti očesa.
In all of the studies, the main measure of effectiveness was how long the patients lived without their cancer getting worse or how long they survived.
V vseh študijah je bilo glavno merilo učinkovitosti čas do poslabšanja bolezni ali čas preživetja bolnikov.
In all of the studies, the main measure of effectiveness was how long the patients lived without their disease getting worse.
V vseh študijah je bilo glavno merilo učinkovitosti čas, ko je bolnik živel, ne da bi se bolezen poslabšala.
In all of the studies, the main measure of effectiveness was the change in four symptoms of allergy affecting the nose.
V vseh študijah je bilo glavno merilo učinkovitosti sprememba štirih simptomov alergije, ki prizadenejo nos.
In all of the studies, the main measure of effectiveness was the change in pressure inside the eye measured in ‘millimetres of mercury’ (mmHg).
V vseh študijah je bilo glavno merilo učinkovitosti sprememba tlaka v očesu, ki se meri v „milimetrih živega srebra“ (mmHg).
In all of the studies, the main measure of effectiveness was the change in pressure inside the eye, measured in units called ‘millimetres of mercury’ (mmHg).
V vseh študijah je bilo glavno merilo učinkovitosti sprememba tlaka v očesu, ki se meri v enotah, imenovanih „milimetri živega srebra“ (mmHg).
In all of the studies, the main measure of effectiveness was the change in the levels of ferritin in the blood.
V vseh študijah je bilo glavno merilo učinkovitosti sprememba ravni feritina v krvi.
In all of the studies, the main measure of effectiveness was the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, over 12 to 28 weeks, or the change in blood glucose levels seen after a meal.
V vseh študijah je bilo glavno merilo učinkovitosti sprememba količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi nadzorovana v obdobju od 12 do 28 tednov, ali sprememba količine glukoze v krvi po jedi.
In all of the studies, the main measure of effectiveness was the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
V vseh študijah je bila glavno merilo učinkovitosti raven glikoziliranega hemoglobina v krvi (HbA1c), ki odraža uspešnost uravnavanja glukoze v krvi.
In all of the studies, the main measure of effectiveness was the number of patients who had undetectable levels of HIV 1 in their blood (viral loads) after 24 or 48 weeks of treatment.
V vseh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so imeli po 24 ali 48 tednih zdravljenja v krvi nezaznavno koncentracijo virusa HIV 1 (virusno breme).
In all of the studies, the main measure of effectiveness was the number of patients who responded to treatment, as defined by disease-specific criteria (American College of Rheumatology response rates for rheumatoid arthritis, and the Psoriatic Arthritis treatment Response Criteria for psoriatic arthritis).
V vseh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so se odzvali na zdravljenje, kot je določeno v merilih za posamezne bolezni (za revmatoidni artritis je to delež odziva, kot ga določa ameriški inštitut za revmatologijo American College of Rheumatology, za psoriatični artritis pa merila odziva na zdravljenje psoriatičnega artritisa).
In all of the studies, the main measure of effectiveness was the number of patients whose infection was cured after treatment.
Glavno merilo učinkovitosti v vseh študijah je bilo število bolnikov, pri katerih je bila okužba po zdravljenju ozdravljena.
In all of the studies, the main measure of effectiveness was the number of patients whose infection was cured after treatment.
Pri vseh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih so bile okužbe po zdravljenju ozdravljene.
In all of the studies, Xolair was compared with placebo (a dummy treatment), when they were added to the patients’ existing treatment.
V vseh študijah so zdravilo Xolair primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ju dodajali bolnikovemu obstoječemu zdravljenju.
In all of the studies, Xolair was compared with placebo, when they were added to the patients’ existing treatment.
V vseh študijah so zdravilo Xolair primerjali s placebom, ki so ju dodajali bolnikovemu obstoječemu zdravljenju.
In all of these studies, the main measure of effectiveness was the change in symptoms after up to 16 weeks.
V vseh študijah je bilo glavno merilo učinkovitosti sprememba v simptomih po 16 tednih.
In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen described in the Summary of Product Characteristics for PREZISTA 100 mg/ml oral suspension, 75 mg, 150 mg, 300 mg or 600 mg tablets.
Pri vseh drugih bolnikih z izkušnjami z ART ali pri bonikih, pri katerih ni rezultatov testiranja genotipa je priporočeno odmerjanje opisano v Povzetkih glavnih značilnosti zdravil PREZISTA 100 mg/ml peroralna suspenzija, PREZISTA 75 mg, 150 mg, 300 mg ali 600 mg tablete.
In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen described in the Summary of Product Characteristics for PREZISTA 100 mg/ml oral suspension,75 mg, 150 mg, 300 mg or 600 mg tablets.
Pri vseh drugih bolnikih z izkušnjami z ART ali pri bonikih, pri katerih ni rezultatov testiranja genotipa je priporočeno odmerjanje opisano v Povzetkih glavnih značilnosti zdravil PREZISTA 100 mg/ml peroralna suspenzija, PREZISTA 75 mg, 150 mg, 300 mg ali 600 mg tablete.
In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food.
Pri vseh drugih bolnikih z izkušnjami z ART, pri katerih ni rezultatov testiranja genotipa je priporočeno odmerjanje 600 mg darunavirja dvakrat na dan, skupaj s 100 mg ritonavirja dvakrat na dan, shrano.
In all packs the needles are attached to the pens ready to inject.
V vseh pakiranjih so igle pritrjene na napolnjene injekcijske peresnike in pripravljene na injiciranje.
In all packs the needles are attached to the syringes ready to inject.
V vseh pakiranjih so igle pritrjene na napolnjene injekcijske brizge in pripravljene na injiciranje.
In all paediatric patients, careful titration to a patient- specific daily dose is needed.
Pri vseh pediatričnih bolnikih je potrebna skrbna titracija dnevnega odmerka, specifičenga za posameznega bolnika.
In all phases of treatment, serum asparagine concentrations decreased within 4 days of the first dose of asparaginase in the treatment phase and remained low for approximately 3 weeks for both Oncaspar and native E. coli L-asparaginase arms.
V vseh fazah zdravljenja se je raven asparagina v serumu znižala v 4 dneh po prvem odmerku asparaginaze v fazi zdravljenja in ostala nizka približno 3 tedne, tako pri zdravilu Oncaspar kot nativni L-asparaginazi iz E. coli .
In all PNH and aHUS clinical studies the most serious adverse reaction was meningococcal septicaemia (see section 4.4).
V vseh kliničnih študijah PNH in aHUS je bil najresnejši neželeni učinek meningokokna sepsa (glejte poglavje 4.4).
In all populations (women 9 – 45 years, men 9 – 26 years), peak anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs cLIA were observed at Month 7.
V obeh populacijah (ženske 9-45 let, moški 9-26 let) so najvišje geometrijske srednje titre cLIA anti-HPV 6, anti-HPV 11, anti-HPV 16 in anti-HPV 18 opažali v 7. mesecu.
In all seven trials, the Exviera dose was 250 mg twice daily and the ombitasvir/paritaprevir/ritonavir dose was 25 mg/150 mg/100 mg once daily.
V vseh sedmih preskušanjih je bil odmerek zdravila Exviera 250 mg dvakrat na dan in odmerek kombinacije ombitasvir/paritaprevir/ritonavir 25/150/100 mg enkrat na dan.
In all seven trials, the Viekirax dose was 25 mg/150 mg/100 mg once daily and the dasabuvir dose was 250 mg twice daily.
V vseh sedmih preskušanjih je bil odmerek zdravila Viekirax 25 mg/150 mg/100 mg enkrat na dan in odmerek dasabuvirja 250 mg dvakrat na dan.
In all situations described below, the benefit/risk balance of Inflectra therapy should be very carefully considered.
V vseh spodaj opisanih okoliščinah je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Inflectra.
In all situations described below, the benefit/risk balance of Remsima therapy should be very carefully considered.
V vseh spodaj opisanih okoliščinah je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Remsima.
In all situations described below, the benefit/risk balance of Simponi therapy should be very carefully considered.
V vseh spodaj opisanih primerih je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Simponi.
In all situations described below, the benefit/risk balance of therapy should be very carefully considered.
V vseh spodaj navedenih okoliščinah je treba korist in tveganje zdravljenja z zdravilom Humira zelo natančno pretehtati.
In all studies (I-VII), patients with raised ALT were asymptomatic and in most cases elevations were transient and resolved on continued treatment.
V vseh študijah (I–VII) so bili bolniki, ki so imeli zvišano ALT, asimptomatski; zvišanje je bilo večinoma prehodno in je med nadaljevanjem zdravljenja minilo.
In all studies the vaccinated sheep and cattle were compared with animals that were not (controls).
V vseh študijah so cepljene ovce in govedo primerjali z necepljenimi živalmi (kontrolna skupina).
In all studies, patients received a 10-minute infusion of 3.0 mg/kg BRINAVESS (or matching placebo) followed by a 15-minute observation period.
V vseh študijah so bolniki dobili 10-minutno infuzijo 3,0 mg/kg zdravila BRINAVESS (ali ujemajoč se placebo), temu pa je sledilo 15-minutno obdobje opazovanja.
In all studies, patients treated with tocilizumab 8 mg/kg had statistically significant higher ACR 20, 50, 70 response rates at 6 months compared to control (Table 2).
V vseh študijah so bili deleži odzivov ACR 20, 50 in 70 po 6 mesecih statistično značilno večji med bolniki, ki so dobivali 8 mg/kg tocilizumaba kot med bolniki v kontrolnih skupinah (preglednica 2).
In all studies, patients treated with tocilizumab 8 mg/kg had statistically significant higher ACR 20, 50, 70 response rates at 6 months compared to control (Table 3).
V vseh študijah so bili deleži odzivov ACR 20, 50 in 70 po 6 mesecih statistično značilno večji med bolniki, ki so dobivali 8 mg/kg tocilizumaba kot med bolniki v kontrolnih skupinah (preglednica 3).
In all studies, the efficacy endpoints were “Count of episodes of laughing and crying” (PBA episodes) and subject scores on the Center for Neurologic Studies - Lability Scale (CNS-LS), a validated 7-item, self-administered questionnaire that provides a quantitative measure of the frequency and severity of PBA.
V vseh študijah je bil opazovani dogodek učinkovitosti „število epizod smeha in joka“ (epizod PBP) in rezultat preskušanca na lestvici labilnosti Centra za nevrološke študije – Lability Scale (CNS-LS), validiranem 7-stopenjskem vprašalniku za samostojno reševanje, ki omogoča kvantitativno meritev pogostnosti in resnosti PBP.
In all studies, the main measure of effectiveness was the change in vision in the affected eye, measured by comparing the number of letters that the patient could see at the end of the treatment period with the number before starting treatment.
Glavno merilo učinkovitosti v vseh študijah je bila sprememba vida prizadetega očesa, ki so jo merili s primerjavo števila črk, ki jih je bolnik lahko videl po zdravljenju, s številom črk, ki jih je videl pred začetkom zdravljenja.
In all studies, the primary endpoint was the proportion of patients with a  75% improvement in the Psoriasis Area and Severity Index score (a PASI 75 response) relative to baseline when assessed one week after a 12-week treatment course.
V vseh študijah je bil primarni cilj študije delež bolnikov z relativnim  75% izboljšanjem psoriaznih predelov in rezultatom indeksa resnosti (PASI 75 odziv) glede na izhodišče, ocenjeno teden dni po zaključku 12 tedenskega zdravljenja.
In all the other trials conducted with INTELENCE in HIV-1 infected patients, the following mutations emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y.
V vseh drugih preskušanjih, opravljenih z zdravilom INTELENCE pri bolnikih, okuženih s HIV-1, so se najpogosteje pojavljale naslednje mutacije: L100I, E138G, V179F, V179I, Y181C in H221Y.
In all the studies, Cubicin was compared with standard treatments for these infections (other antibiotics such as vancomycin or one of the penicillins, including oxacillin, cloxacillin, flucloxacillin and nafcillin).
V vseh študijah so zdravilo Cubicin primerjali s standardnim zdravljenjem, ki se uporablja pri takih okužbah (drugimi protibakterijskimi zdravili, npr. vankomicinom ali enim od penicilinov, vključno z oksacilinom, kloksacilinom, flukloksacilinom in nafcilinom).
In all three adult studies, doses of Invega between 3 and 15 mg a day were compared with placebo (a dummy treatment) and with olanzapine (another antipsychotic medicine).
V vseh treh študijah z odraslimi bolniki so 3- do 15-miligramske dnevne odmerke zdravila Invega primerjali s placebom (zdravilom brez zdravilne učinkovine) in olanzapinom (drugim antipsihotikom).
In all three main studies, Kaletra reduced viral load (the amount of virus found in the blood).
V vseh treh glavnih študijah je zdravilo Kaletra zmanjšalo virusno breme (količino virusa v krvi).
In all three phase III studies (see table 3), rivaroxaban significantly reduced the rate of total VTE (any venographically detected or symptomatic DVT, non-fatal PE and death) and major VTE (proximal DVT, non-fatal PE and VTE-related death), the pre-specified primary and major secondary efficacy endpoints.
V vseh treh kliničnih preskušanjih III. faze (glejte preglednico 3) je rivaroksaban značilno zmanjšal delež vseh VTE (z venografijo potrjene ali simptomatske GVT, neusodne PE in smrti), kakor tudi težjih oblik VTE (proksimalne GVT, neusodne PE in smrti, povezane z VTE), kar so bili vnaprej določeni primarni in pomembni sekundarni cilji preskušanja.
In all three studies, INVEGA was superior to placebo on PSP and CGI-S.
Zdravilo INVEGA je bilo v vseh treh študijah boljše od placeba po lestvicah PSP in CGI-S.
In all three studies, Kaletra and the comparator medicines were combined with other antiviral medicines.
V vseh treh študijah so bili zdravilo Kaletra in primerjalna zdravila kombinirani z drugimi protivirusnimi zdravili.